ClinicalTrials.gg
Not yet recruitingNCT07891780Updated Oct 23, 2026

Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients

A Phase 2 interventional study of Epinephrine Nasal Spray, 2.5 mg and Epinephrine Nasal Spray, 5.25 mg in Epinephrine, Hypersensitivity, Immediate and Anaphylaxis, sponsored by Hikma Pharmaceuticals USA Inc.. Not yet recruiting at 2 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionAnaphylaxisRegistry: Hypersensitivity, ImmediateReclassifiedWhy we changed it
Registry
Hypersensitivity, Immediate — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anaphylaxis
Why
  1. The study's listed conditions name Anaphylaxis, a narrower term within Hypersensitivity, Immediate.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hikma Pharmaceuticals USA Inc. · Phase 2, Interventional, and Basic science

Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Anaphylaxis with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Anaphylaxis · United States.

Planned enrollment
3rd of 12
44 · median 24
Started
2026
with 3 others
Phase 2
4 of 26
2 open now
Registered
24th of 26
by date

Among the 26 studies in Anaphylaxis with a site in United States, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2, and was the 24th registered.

Anaphylaxis

101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.

Browse Anaphylaxis studies →

Open to participants now

7 of the 26 studies in Anaphylaxis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Anaphylaxis studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Anaphylaxis with a site in United States, or all of them as a file.
02

Study summary

This Phase 2, open-label, single-arm study will evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose of epinephrine nasal spray (ENS) in children and adolescents 2 to 17 years of age with a diagnosed Type I allergy.

Approximately 44 participants will be enrolled in two body-weight cohorts.

  • Participants weighing >30 kg will receive a single 5.25 mg dose of ENS, and
  • Participants weighing ≥15 kg to ≤30 kg will receive a single 2.5 mg dose of ENS.

The study will assess plasma epinephrine concentrations, changes in blood pressure and pulse rate, and safety and tolerability following administration of ENS. Participants will be monitored for 4 hours after dosing and will complete safety follow-up through approximately Day 15.

03

Conditions studied

  • Epinephrine
  • Hypersensitivity, Immediate
  • Anaphylaxis

Browse trials for

04

In context

Anaphylaxis Reclassified

101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.

This study's planned enrollment of 44 is close to the median of 40 across 51 interventional studies indexed under Anaphylaxis.

Browse Anaphylaxis studies →

Lead sponsor

This is the only study on the registry with Hikma Pharmaceuticals USA Inc. as lead sponsor.

Compared within Anaphylaxis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity, Immediate. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female children and adolescents aged between 2 and 17 years (inclusive) at the time of Screening.
  • Diagnosed with type I allergy with food or venom allergy, which is prone to anaphylactic reactions and requires the prescription of epinephrine products.
  • Body weight ≥15 kg (33 lbs) measured in light clothing and without shoes.
  • Have a within the 5-95% percentile, considering the regional, sex and age-specific growth charts.
  • Signed form (ICF) by the parent/legally authorised representative (LAR).
  • Signed assent form by the child/adolescent.
  • Willingness to comply with the requirements and restrictions listed in the ICF and this Clinical Study Protocol.
  • Females of must agree to use highly effective methods of from the beginning of Screening until the last visit.

Note: acceptable highly effective methods of contraception include methods that can achieve a failure rate of less than 1% per year when used consistently and correctly: the intrauterine device; intrauterine system; bilateral tubal occlusion (must be documented); oral, intravaginal, transdermal, injectable, and implantable methods of hormonal contraception associated with inhibition of ovulation (combined estrogen and progesterone containing; or progesterone-only hormonal contraception); vasectomised partner (must be documented); or sexual abstinence (only when it is the usual and preferred lifestyle of the participant).

Note 1: Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraception method.

Note 2: Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the surgical success.

Note 3: In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the study participant

  • If the participant is a fertile male, the participant must use a condom, or his female partner of childbearing potential must use a highly effective form of contraception described in the note above, or the participant can practice abstinence (only when it is the usual and preferred lifestyle of the participant) from the beginning of Screening until the last visit.

Exclusion criteria

Exclusion Criteria:

  • Prior nasal fractures, severe nasal injuries or surgeries, nostril or septum piercings, as well as presence of nasal obstruction, that could interfere with nasal spray administration.
  • Known cardiac comorbidity (including hypertension, cardiac arrhythmias, tachycardia [PR >140/min in participants ≤10 years old or >100/min in participants >10 years], coronary artery disease, or any other structural or electrophysiological diagnosis).

Note: To account for stress-related elevations, if BP and/or PR are elevated on Day 1 pre-dose, the Investigator may consider repeating the measurement prior to participant exclusion. If BP and/or PR are elevated on repeated measurements, the participant should be excluded.

  • Known increased risk of cerebrovascular haemorrhage (i.e., arteriovenous malformations, aneurysms, recent head traumas, or history of brain tumours).
  • Diagnosis of hyperthyroidism, diabetes, hepatic or renal dysfunction.
  • Presence of acute illness, such as common cold, flu or other acute infection, within 7 days prior to Day 1.
  • History of neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardise the safety of the participant or impact the validity of the study results.
  • Clinically significant findings at Screening in vital signs measurements, findings, physical and nasal cavity examination.
  • Positive urine screen for alcohol, drugs of abuse and cotinine for participants ≥12 years of age.
  • Use of the following substances within 72 hours prior to Day 1: any intranasal or sinus medication (including , decongestants, saline washes).
  • Use of the following substances within 14 days prior to Day 1: beta-adrenergic blockers, tricyclic antidepressants, monoamine oxidase inhibitors.
  • Use of the following substances within 24 hours prior to Day 1: other catecholamines (e.g., norepinephrine, dopamine) or vasopressors.
  • Use of the following substances within 7 days prior to Day 1: ergot alkaloids; levothyroxine (if not on a stable, replacement dose); strong inhibitors or inducers of , CYP2D6, CYP2C9, and CYP1A2 enzymes; catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone); antiarrhythmics, other alpha-adrenergic blockers, reserpine, and clonidine-type antihypertensives.
  • Participant not willing to avoid using methylxanthine-containing products (e.g., chocolate, cocoa, or cola) within 24 hours before dosing on Day 1.
  • Known reaction or sensitivity to epinephrine or any of the ingredients of the product, including sodium bisulfite.
  • Females who are pregnant or breastfeeding.
  • Lifetime use of tobacco, vape or nicotine-containing products.
  • Participation in another clinical study with any medicinal product within 90 days before dosing.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    ≥15 kg to ≤30 kg

    Epinephrine Nasal Spray, 2.5 mg

    Drug: Epinephrine Nasal Spray, 2.5 mg

  • Experimental
    >30 kg

    Epinephrine Nasal Spray, 5.25 mg

    Drug: Epinephrine Nasal Spray, 5.25 mg

Interventions

  • DrugEpinephrine Nasal Spray, 2.5 mg

    A single dose of epinephrine nasal spray (ENS) will be administered intranasally based on body weight: 2.5 mg for participants weighing ≥15 to ≤30 kg.

  • DrugEpinephrine Nasal Spray, 5.25 mg

    A single dose of epinephrine nasal spray (ENS) will be administered intranasally based on body weight: 5.25 mg for participants weighing \>30 kg.

07

What researchers measure

Primary outcomes

  1. To assess the PK of a single dose of ENS in children and adolescents (2-17 years)

    Epinephrine Maximal concentration (Cmax)

    Time frame: 0-240 minutes

  2. To assess the PK of a single dose of ENS in children and adolescents (2-17 years)

    Time at maximal concentration (Tmax)

    Time frame: 0-240 minutes

  3. To assess the PK of a single dose of ENS in children and adolescents (2-17 years)

    Area under the curve 0-240 min. (AUC0-240) based on observed plasma concentration-time data

    Time frame: 0-240 minutes

Secondary outcomes

  1. To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)

    Maximum effect (Emax) for Systolic blood pressure (SBP) until 240 min. post-dose.

    Time frame: until 240 minutes post-dose

  2. To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)

    Maximum effect (Emax) for Diastolic blood pressure (DBP) until 240 min. post-dose.

    Time frame: until 240 minutes post-dose

  3. To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)

    Maximum effect (Emax) for Pulse rate (PR) until 240 min. post-dose.

    Time frame: until 240 minutes post-dose

  4. To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)

    Maximum effect (Emax) for Mean Arterial Pressure (MAP) until 240 min. post-dose.

    Time frame: until 240 minutes post-dose

  5. Occurrence of Treatment-emergent Adverse Events (TEAE) [Safety and Tolerability]

    Occurrence of Treatment-emergent Adverse Events (TEAE) until Day 15, after a single dose of ENS in children and adolescents (2-17 years)

    Time frame: 15 days

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for May 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Oct 23, 2026
StartEst.
Sep 28, 2026
Primary completionEst.
May 8, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07891780
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
May 8, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Senior Principal Scientist, Clinical R&D
Contact
usclinicalgeneralemail@hikma.com
(614) 276-4000
Nageshwar Thudi, PhD
study director · Hikma Pharmaceuticals USA Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion